This company develops a novel platform for drug formulation and dose preparation by integrating microfluidics manufacturing, robotics, and AI. The platform addresses the scaling challenges associated with complex next-generation and curative therapies. This technology aims to accelerate the transition to curative medicine and improve patient access.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIFounders
Product
Problem
The cell and gene therapy (CGT) field faces infrastructure limitations in dose preparation and administration, hindering the scalability and accessibility of these advanced treatments. Manual processes are prone to variability, limiting the number of healthcare providers capable of delivering CGTs and potentially delaying patient access to curative therapies.
Solution
Cellular Vehicles develops the Odyssey System, an automated platform designed to standardize and streamline cell and gene therapy dose preparation at the point of care. The system automates critical steps such as thawing, washing, and dosing, reducing manual handling and variability. By simplifying the "last mile" of CGT delivery, the Odyssey System increases the capacity of healthcare facilities to administer these therapies, enabling wider patient access. The platform aims to accelerate the transition to curative cell-based therapies by addressing key infrastructure bottlenecks in the CGT supply chain.
Target Audience
The primary target audience includes hospitals, healthcare providers, and biopharmaceutical companies involved in the delivery of cell and gene therapies.
Features
- Automated thawing, washing, and dosing of cell and gene therapies
- Standardized dose preparation protocols to minimize variability
- Integrated system designed for hospital-side deployment
- Modular design to accommodate various CGT products and workflows
- Closed system to maintain sterility and minimize contamination risk